Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.
Journal
Bioconjugate chemistry
ISSN: 1520-4812
Titre abrégé: Bioconjug Chem
Pays: United States
ID NLM: 9010319
Informations de publication
Date de publication:
21 04 2021
21 04 2021
Historique:
pubmed:
6
4
2021
medline:
15
9
2021
entrez:
5
4
2021
Statut:
ppublish
Résumé
Pretargeted imaging and radioimmunotherapy approaches are designed to have superior targeting properties over directly targeted antibodies but impose more complex pharmacology, which hinders efforts to optimize the ligands prior to human applications. Human embryonic kidney 293T cells expressing the humanized single-chain variable fragment (scFv) C825 (huC825) with high-affinity for DOTA-haptens (293T-huC825) in a transmembrane-anchored format eliminated the requirement to use other pretargeting reagents and provided a simplified, accelerated assay of radiohapten capture while offering normalized cell surface expression of the molecular target of interest. Using binding assays,
Identifiants
pubmed: 33819023
doi: 10.1021/acs.bioconjchem.0c00595
pmc: PMC8284561
mid: NIHMS1715935
doi:
Substances chimiques
Haptens
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-654Subventions
Organisme : NCI NIH HHS
ID : R01 CA055349
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA241894
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA023766
Pays : United States
Organisme : NIBIB NIH HHS
ID : F32 EB025050
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA192937
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA239511
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233896
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243895
Pays : United States
Références
J Nucl Med. 1999 Nov;40(11):1935-46
pubmed: 10565792
Blood. 2018 Feb 8;131(6):611-620
pubmed: 29158362
J Nucl Med. 2017 Nov;58(11):1735-1742
pubmed: 28705917
Cancer Res. 2016 Nov 15;76(22):6669-6679
pubmed: 27590740
Nucl Med Biol. 2011 Feb;38(2):223-33
pubmed: 21315278
Mol Cancer Ther. 2014 Jul;13(7):1803-12
pubmed: 24944121
J Nucl Med. 2008 Nov;49(11):1828-35
pubmed: 18927335
Nat Rev Cancer. 2015 Jun;15(6):347-60
pubmed: 25998714
Mol Imaging Biol. 2011 Apr;13(2):215-21
pubmed: 20533093
Cancer Res. 1994 Nov 15;54(22):5937-46
pubmed: 7954426
Bioconjug Chem. 2020 Mar 18;31(3):501-506
pubmed: 31891487
J Nucl Med. 2018 Dec;59(12):1894-1900
pubmed: 29903928
Theranostics. 2018 Oct 6;8(18):5106-5125
pubmed: 30429889
Eur J Nucl Med Mol Imaging. 2016 May;43(5):925-937
pubmed: 26596724
J Nucl Med. 2010 Mar;51(3):471-6
pubmed: 20197451
J Nucl Med. 2019 Nov;60(11):1622-1628
pubmed: 30954941
J Nucl Med. 2008 Sep;49(9):1546-54
pubmed: 18703602
Clin Cancer Res. 2010 Nov 1;16(21):5303-11
pubmed: 20858843
Front Immunol. 2015 Oct 08;6:505
pubmed: 26500646
J Nucl Med. 2019 Dec;60(12):1802-1811
pubmed: 31201251
Nature. 1985 Jul 18-24;316(6025):265-8
pubmed: 3927170
Theranostics. 2020 Sep 14;10(25):11359-11375
pubmed: 33052220
Mol Cancer Ther. 2020 Dec;19(12):2575-2584
pubmed: 33082277